SKBI [SKYSTAR BIO-PHARMACEUTICAL] SC 13G/A: (Original Filing)
[]
[FORM 10-Q (Mark One) x June 30, 2013 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
[FORM 10-Q (Mark One) x June 30, 2013 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
[FORM 10-Q (Mark One) x June 30, 2013 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]
[Sinovac Schedules 2013 Annual Meeting of Shareholders BEIJING, July 19, 2013 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2013 Annual Meeting of Shareholders on Wednesday, August 21, 2013 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [Sinovac to Host Conference Call to Report Second Quarter 2013 Unaudited Financial Results BEIJING, July 31, 2013 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2013, after market closes on Tuesday, August 13, 2013 EDT. The Company] [Sinovac Reports Unaudited Second Quarter 2013 Financial Results - Conference call scheduled for Wednesday, August 14, 2013 at 8:00 AM EDT BEIJING, Aug. 13, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. ( SVA ), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2013. Second] []
[Sinovac Schedules 2013 Annual Meeting of Shareholders BEIJING, July 19, 2013 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2013 Annual Meeting of Shareholders on Wednesday, August 21, 2013 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [Sinovac to Host Conference Call to Report Second Quarter 2013 Unaudited Financial Results BEIJING, July 31, 2013 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2013, after market closes on Tuesday, August 13, 2013 EDT. The Company] [Sinovac Reports Unaudited Second Quarter 2013 Financial Results - Conference call scheduled for Wednesday, August 14, 2013 at 8:00 AM EDT BEIJING, Aug. 13, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. ( SVA ), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2013. Second] []
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: June 30, 2013 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: June 30, 2013 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:090678 202 o o o (Check One): x o o For Period Ended:June 30, 2013 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall benstrued to imply that themmission has verified any informationntained herein.]